不同剂量奥曲肽治疗重症急性胰腺炎的疗效及安全性比较

Comparison on effect and safety of different-dose octreotide in treatment of severe acute pancreatitis

目的观察比较不同剂量奥曲肽治疗重症急性胰腺炎的疗效及安全性。方法选取医院就诊的重症急性胰腺炎患者82例,均采用奥曲肽治疗,根据服用剂量,将采用0.6 mg/d奥曲肽治疗者设定为对照组(41例),采用1.2 mg/d治疗者设定为加倍组(41例),观察2组发热、腹胀、腹痛消失时间,血淀粉酶复常时间及APACHEⅡ评分等指标,观察2组临床疗效和不良反应发生情况。结果加倍组治疗后发热、腹胀、腹痛消失时间,血淀粉酶复常时间均短于对照组,APACHEⅡ评分低于对照组(P均<0.01);加倍组临床总有效率为97.56%,高于对照组的78.05%(P<0.05)。加倍组不良反应发生率为7.32%,对照组不良反应发生率为9.76%,2组比较差异无统计学意义(P>0.05)。结论加倍剂量奥曲肽治疗重症急性胰腺炎,可有效改善机体相关指标,提高临床有效率,且安全性好,值得临床推广应用。

Objective To compare and analyze on the effect and safety of different-dose octreotide in treatment of se- vere acute panereatitis. Methods Fifty-eight patients in the hospital suffered from acute pancreatitis were treated with octreoti- de. According to the dosage, patients with 0.6 mg/d octreotide treatment were selected as the control group, and with 1.2 mg/ d octreotide treatment were as the double-set group. Fever, abdominal distension, abdominal pain disappearance times, blood amylase time and APACHE II score, clinical effect and adverse reactions were compared and observed in the two groups. Re- suits Fever, abdominal distension, abdominal pain disappearance times, and blood amylase time in the double-set group were significantly shorter than those in the control group, and APACHE score was significantly lower than that in the control group, with statistically significant differences （ all P 〈 0.01 ）. Clinical effective rate of the double-set group was 97.56%, higher than that of 78.05% of the control group,with statistically significant differences （P 〈 0.05 ）. The incidence of adverse reactions was 7.32% in the doubling group and 9.76% in the control group. There was no significant difference between the two groups （ P 〉 0.05 ）. Conclusion Repeated dose octreotide in treatment of severe acute pancreatitis, can effectively improve the body- related indicators, clinical efficiency, and safety. It is worthy of clinical application.